Apellis Pharmaceuticals Inc (APLS)
43.22
+1.22
(+2.90%)
USD |
NASDAQ |
May 20, 16:00
43.22
0.00 (0.00%)
After-Hours: 20:00
Apellis Pharmaceuticals Gross Profit Margin (Quarterly): 88.27% for March 31, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 88.27% |
| December 31, 2023 | 86.40% |
| September 30, 2023 | 79.70% |
| June 30, 2023 | 91.18% |
| March 31, 2023 | 82.59% |
| December 31, 2022 | 87.09% |
| Date | Value |
|---|---|
| September 30, 2022 | 93.74% |
| June 30, 2022 | 99.50% |
| March 31, 2022 | 91.33% |
| December 31, 2021 | 91.62% |
| September 30, 2021 | 97.36% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
79.70%
Minimum
Sep 2023
99.50%
Maximum
Jun 2022
89.89%
Average
91.18%
Median
Jun 2023
Gross Profit Margin (Quarterly) Benchmarks
| Inspire Medical Systems Inc | 84.91% |
| Sarepta Therapeutics Inc | 87.77% |
| Blueprint Medicines Corp | 96.68% |
| Alnylam Pharmaceuticals Inc | 86.65% |
| Cytokinetics Inc | -9.67K% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -143.8% |
| Return on Assets | -48.15% |
| Return on Invested Capital | -108.9% |
| Profit Margin (Quarterly) | -38.55% |
| Operating Margin (Quarterly) | -36.03% |
| Return on Net Operating Assets | -119.7% |